Edition:
United States

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

103.20EUR
24 Feb 2017
Change (% chg)

€0.45 (+0.44%)
Prev Close
€102.75
Open
€102.50
Day's High
€103.25
Day's Low
€102.15
Volume
620,156
Avg. Vol
419,909
52-wk High
€103.95
52-wk Low
€71.15

Latest Key Developments (Source: Significant Developments)

India's Merck Ltd June-qtr profit up about 6 pct
Monday, 25 Jul 2016 06:24am EDT 

Merck Ltd : India's Merck Ltd - June-quarter net profit 179 million rupees; net sales 2.53 billion rupees . Net profit in June-quarter last year was 168.6 million rupees; net sales was 2.41 billion rupees .  Full Article

Merck says EMA accepts cladribine for review marketing authorisation application
Monday, 18 Jul 2016 02:00am EDT 

Merck Kgaa :EMA has accepted for review marketing authorization application (MAA) of investigational product cladribine tablets for treatment of relapsing-remitting multiple sclerosis.  Full Article

BRIEF-Pfizer and Germany's Merck KGaA initiate phase III trial
Thursday, 7 Jul 2016 11:56am EDT 

Pfizer Inc : Merck KGaA and Pfizer initiate phase III trial to evaluate avelumab as first-line treatment for ovarian cancer . New investigational regimen will evaluate avelumab in extending progression-free survival in treatment-naïve women .First phase III trial evaluating addition of an immune checkpoint inhibitor to standard of care in first-line ovarian cancer.  Full Article

Pfizer and Merck initiate phase III trial
Wednesday, 6 Jul 2016 08:00am EDT 

Pfizer Inc : Merck and Pfizer initiate phase III trial to evaluate avelumab as first-line treatment for ovarian cancer . New investigational regimen will evaluate avelumab in extending progression-free survival in treatment-naïve women .First phase III trial evaluating addition of an immune checkpoint inhibitor to standard of care in first-line ovarian cancer.  Full Article

Merck KGaA says plans to apply for authorization for Avelumab in H2
Monday, 20 Jun 2016 05:00am EDT 

Merck Kgaa : Says plan to apply for marketing authorization for avelumab against merkel cell carcinoma in h2 2016 Further company coverage: [MRCG.DE] ((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1272;)).  Full Article

Merck KGaA partners with Array BioPharma, Pierre Fabre on mCRC phase iii trial
Saturday, 4 Jun 2016 09:23am EDT 

Merck KGaA : Says partners with Array BioPharma and Pierre Fabre to initiate braf-mutant mCRC phase iii trial Further company coverage: [MRCG.DE] ((frankfurt.newsroom@thomsonreuters.com; +496975651270;)).  Full Article

Merck KGaA publishes Chinese Phase III study for Erbitux - Reuters
Monday, 25 Apr 2016 02:11am EDT 

Merck KGaA:Says phase III tailor landmark study demonstrates significant benefits of erbitux in combination with folfox over folfox alone - Reuters.Says marks a major milestone of merck’s oncology strategy including expansion in growth markets.Says will work with relevant authorities to make erbitux available for patients in china as a first - line treatment as soon as possible.  Full Article

Merck KGaA issues FY 2016 outlook, to propose FY 2015 dividend
Tuesday, 8 Mar 2016 01:00am EST 

Merck KGaA:Expects slight organic sales growth in 2016, low double-digit pct increase in adjusted EBITDA.Proposes annual dividend of 1.05 euros per share vs poll avg of 1.09 euros per share.FY 2016 revenue 15,310 million euros - Thomson Reuters I/B/E/S.FY 2016 EBITDA 4,314 million euros - Thomson Reuters I/B/E/S.  Full Article

Merck KGaA, Darmstadt, Germany, Pfizer and Verastem announce combination trial of Avelumab and VS-6063 in ovarian cancer
Thursday, 3 Mar 2016 07:00am EST 

Merck KGaA Merck KGaA, Darmstadt, Germany, Pfizer and Verastem:Says have entered into an agreement to evaluate avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem's VS-6063, an investigational focal adhesion kinase inhibitor, in patients with advanced ovarian cancer.Financial terms of the agreement have not been disclosed.Phase I/Ib clinical trial is expected to begin in the second half of 2016.  Full Article

Merck KGaA and Biocartis to collaborate on new liquid biopsy technology for RAS biomarker testing
Wednesday, 6 Jan 2016 07:00pm EST 

Merck KGaA:Merck and Biocartis to collaborate on new liquid biopsy technology for RAS biomarker testing.Merck becomes first pharmaceutical company to collaborate with multiple diagnostic providers to support RAS biomarker testing.Collaboration allows Merck to provide complementary molecular testing solutions to various laboratory segments.  Full Article

More From Around the Web

BRIEF-Ablynx's partner Merck reports encouraging results with nanobody

* Ablynx's partner, Merck KGaA, reports encouraging results with the bi-specific nanobody anti-il-17a/f (m1095) in a phase ib clinical study in patients with psoriasis